2-[3-[2-[[Cyclopropanecarbonyl(ethyl)amino]methyl]-4-methylphenyl]-2,5,6-trifluoro-4-methoxyphenyl]acetic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[3-[2-[[Cyclopropanecarbonyl(ethyl)amino]methyl]-4-methylphenyl]-2,5,6-trifluoro-4-methoxyphenyl]acetic acid
• 英文别名: 2-[3-[2-[[cyclopropanecarbonyl(ethyl)amino]methyl]-4-methylphenyl]-2,5,6-trifluoro-4-methoxyphenyl]acetic acid
• 化学式: C₂₃H₂₄F₃NO₄
• 分子量: 435.4
• InChiKey: UONVEQGFCNPTME-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Non-invasive biomarker to identify subject at risk of preterm delivery
  申请人：NYU Winthrop Hospital

  公开号：US10408838B2

  公开（公告）日：2019-09-10

  Methods for diagnosis to allow prediction of the likelihood of preterm birth based upon the concentration of lipocalin-type prostaglandin D2 synthase (L-PGDS) in cervical vaginal secretions. In addition, specific prostaglandin D2 receptor antagonists may represent novel tocolytic therapeutics.

  根据宫颈阴道分泌物中脂钙素型前列腺素 D2 合酶（L-PGDS）的浓度预测早产可能性的诊断方法。此外，特异性前列腺素 D2 受体拮抗剂可能是新的溶血疗法。
• NON-INVASIVE BIOMARKER TO IDENTIFY SUBJECTS AT RISK OF PRETERM DELIVERY
  申请人：Winthrop-University Hospital

  公开号：EP2912458A1

  公开（公告）日：2015-09-02
• NON-INVASIVE BIOMARKER TO IDENTIFY SUBJECT AT RISK OF PRETERM DELIVERY
  申请人：WINTHROP-UNIVERSITY HOSPITAL

  公开号：US20150285800A1

  公开（公告）日：2015-10-08

  Methods for diagnosis to allow prediction of the likelihood of preterm birth based upon the concentration of lipocalin-type prostaglandin D2 synthase (L-PGDS) in cervical vaginal secretions. In addition, specific prostaglandin D2 receptor antagonists may represent novel tocolytic therapeutics.
• US9797903B2
  申请人：——

  公开号：US9797903B2

  公开（公告）日：2017-10-24
• [EN] NON-INVASIVE BIOMARKER TO IDENTIFY SUBJECTS AT RISK OF PRETERM DELIVERY<br/>[FR] BIOMARQUEUR NON INVASIF PERMETTANT D'IDENTIFIER DES SUJETS RISQUANT UN ACCOUCHEMENT AVANT TERME
  申请人：UNIV WINTHROP HOSPITAL

  公开号：WO2014066568A1

  公开（公告）日：2014-05-01

  Methods for diagnosis to allow prediction of the likelihood of pretenn birth based upon the concentration of lipocalin-type prostaglandin D2 synthase (L-PGDS) in cervical vaginal secretions. In addition, specific prostaglandin D2 receptor antagonists may represent novel tocolytic therapeutics.